Startup profile · funding coverage
Dyno Therapeutics
AI-designed AAV capsids for gene therapy — CapsidMap platform partnered with Novartis, Sarepta, Roche.
Stage
series a
Status
private
Coverage
full
Why Dyno Therapeutics is interesting
a16z-led $100M Series A with Lux and CRV — a gene-delivery bottleneck play as pharma outsources capsid engineering.
Key facts
- Series A (May 2021): $100M led by a16z; Lux Capital and CRV participated (Dyno press)
- Seed: Polaris and CRV founding investors (company press)
Investors in our directory
Funds linked from Dyno Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Dyno Therapeutics's financing or category context.
FAQs about Dyno Therapeutics
Funding context and why this company shows up in venture coverage.
Dyno uses machine learning to design adeno-associated virus (AAV) capsids for gene therapy — improving how therapeutic genes are delivered to target tissues.
Andreessen Horowitz (/fund/andreessen-horowitz) led the $100M Series A in May 2021. Lux Capital (/fund/lux-capital) and CRV (/fund/crv) participated. Polaris backed the seed.
Dyno raised a $100M Series A in May 2021. It remains a private biotech company with pharma partnership revenue.
Gene therapy efficacy depends on getting DNA into the right cells — Dyno applies AI to capsid design, a bottleneck pharma increasingly outsources.
No. Dyno Therapeutics is privately held as of July 2026.
Last updated: 2026-07-24